Seattle Genetics Company Profile (NASDAQ:SGEN)

Analyst Ratings

Consensus Ratings for Seattle Genetics (NASDAQ:SGEN) (?)
Ratings Breakdown: 1 Sell Rating(s), 6 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Hold (Score: 2.47)
Consensus Price Target: $54.42 (13.43% upside)

Analysts' Ratings History for Seattle Genetics (NASDAQ:SGEN)
Show:
DateFirmActionRatingPrice TargetActions
7/27/2016RBC Capital MarketsReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2016Barclays PLCBoost Price TargetOverweight$48.00 -> $53.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2016SunTrust Banks Inc.Boost Price TargetNeutral$34.00 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2016Cantor FitzgeraldDowngradeBuy -> Hold$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Needham & Company LLCReiterated RatingBuy$60.00 -> $72.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016HC WainwrightReiterated RatingBuy$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016Oppenheimer Holdings Inc.Reiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2016Leerink SwannLower Price TargetOutperform$56.00 -> $52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2016Piper Jaffray Cos.Lower Price TargetNeutral$44.00 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2016JPMorgan Chase & Co.Lower Price TargetNeutral$45.00 -> $43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2015Goldman Sachs Group Inc.Initiated CoverageSell$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/14/2015Royal Bank Of CanadaLower Price TargetOutperform$56.00 -> $54.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/25/2015William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2015Bank of America Corp.Reiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2015Jefferies GroupSet Price TargetBuy$53.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Seattle Genetics (NASDAQ:SGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016        
7/26/2016Q216($0.32)($0.23)$94.56 million$95.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2016Q116($0.09)($0.15)$116.49 million$111.15 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2016Q415($0.20)($0.18)$88.00 million$93.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q315($0.20)($0.21)$82.35 million$84.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q215($0.26)($0.38)$78.21 million$77.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q1($0.19)($0.17)$74.57 million$82.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2015Q414($0.25)($0.22)$68.34 million$74.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314($0.24)($0.13)$66.90 million$75.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214($0.23)($0.14)$65.04 million$68.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114($0.21)($0.13)$64.62 million$68.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2014Q413($0.24)($0.13)$59.50 million$67.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.22)($0.19)$57.79 million$71.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2013Q2 2013($0.20)($0.06)$58.12 million$773.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.19)($0.14)$53.72 million$57.32 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2013Q4 2012($0.10)($0.09)$57.21 million$63.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.14)($0.12)$52.79 million$49.83 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2012($0.15)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012($0.11)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2012($0.31)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011($0.46)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Seattle Genetics (NASDAQ:SGEN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.15)($0.15)($0.15)
Q2 20161($0.29)($0.29)($0.29)
Q3 20161($0.35)($0.35)($0.35)
Q4 20161($0.36)($0.36)($0.36)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Seattle Genetics (NASDAQ:SGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Seattle Genetics (NASDAQ:SGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/6/2016Clay B. SiegallCEOSell7,618$40.56$308,986.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016Clay B SiegallCEOSell22,083$43.59$962,597.97View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2016Darren S ClineEVPSell3,366$42.07$141,607.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2016Clay B SiegallCEOSell48,660$40.41$1,966,350.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Clay B SiegallCEOSell8,400$40.09$336,756.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Clay B SiegallCEOSell6,700$40.12$268,804.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2016Clay B SiegallCEOSell7,618$35.16$267,848.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2016Clay B SiegallCEOSell800$40.00$32,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Clay B SiegallCEOSell7,618$36.12$275,162.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2016Clay B SiegallCEOSell15,236$35.52$541,182.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2016Clay B SiegallCEOSell4,282$35.01$149,912.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Felix BakerDirectorBuy124,065$31.85$3,951,470.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Felix BakerDirectorBuy1,349,237$32.10$43,310,507.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Felix BakerDirectorBuy661,093$32.08$21,207,863.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2016Felix BakerDirectorBuy118,941$33.77$4,016,637.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2016Felix BakerDirectorBuy694,666$32.46$22,548,858.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Felix BakerDirectorBuy502,523$22.66$11,387,171.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2016Felix BakerDirectorBuy675,922$31.77$21,474,041.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Felix BakerDirectorBuy24,200$31.24$756,008.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/29/2016Felix BakerDirectorBuy251,722$30.39$7,649,831.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2016Felix BakerDirectorBuy314,508$29.55$9,293,711.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016Felix BakerDirectorBuy1,001,471$29.63$29,673,585.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Felix BakerDirectorBuy1,269,147$30.43$38,620,143.21View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016John A. OrwinDirectorBuy2,000$28.33$56,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Vaughn B. HimesEVPSell40,500$39.94$1,617,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Clay B. SiegallCEOSell3,720$39.99$148,762.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2015Felix BakerDirectorBuy329,358$43.94$14,471,990.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Clay B SiegallCEOSell87,473$45.40$3,971,274.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Darren S ClineSVPSell5,769$45.68$263,527.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015Felix BakerDirectorBuy934,624$42.95$40,142,100.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015Felix BakerDirectorBuy507,300$43.76$22,199,448.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2015Eric DobmeierCOOSell17,452$42.50$741,710.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2015Felix BakerDirectorBuy417,924$41.94$17,527,732.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/5/2015David W GryskaDirectorSell10,000$43.57$435,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2015Clay B. SiegallCEOSell3,718$43.14$160,394.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Clay B. SiegallCEOSell3,718$41.30$153,553.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Clay B. SiegallCEOSell3,718$40.12$149,166.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Clay B. SiegallCEOSell31,754$42.02$1,334,303.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Darren S. ClineSVPSell2,231$42.02$93,746.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Eric DobmeierCOOSell8,548$42.02$359,186.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Jonathan G. DrachmanCMOSell4,462$42.02$187,493.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Todd E. SimpsonCFOSell5,825$42.02$244,766.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Vaughn B. HimesEVPSell5,997$42.02$251,993.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Clay B SiegallCEOSell3,718$46.94$174,522.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2015Clay B SiegallCEOSell3,718$45.72$169,986.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2015Felix BakerDirectorBuy950,886$42.49$40,403,146.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2015Eric DobmeierCOOSell17,074$40.38$689,448.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2015Felix BakerDirectorBuy1,032,664$35.56$36,721,531.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Felix BakerDirectorBuy285,036$34.66$9,879,347.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Felix BakerDirectorBuy275,717$34.66$9,556,351.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2015Felix BakerDirectorBuy448,841$34.84$15,637,620.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2015Felix BakerDirectorBuy281,115$33.92$9,535,420.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2015Clay B SiegallCEOSell16,804$31.80$534,367.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2014Felix BakerDirectorBuy2,883,378$31.86$91,864,423.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Felix BakerDirectorBuy1,247,896$33.82$42,203,842.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Felix BakerDirectorBuy128,430$34.16$4,387,168.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Felix BakerDirectorBuy465,316$32.93$15,322,855.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Vaughn B HimesEVPSell10,000$37.52$375,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Felix BakerDirectorBuy1,653,925$34.56$57,159,648.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014Clay B SiegallCEOSell5,600$42.54$238,224.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Clay B SiegallCEOSell11,200$40.38$452,256.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Clay B SiegallCEOSell2,700$40.05$108,135.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014Felix BakerDirectorBuy216,595$39.92$8,646,472.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Clay B SiegallCEOSell11,200$40.14$449,568.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014Felix BakerDirectorBuy546,252$38.16$20,844,976.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2014Felix BakerDirectorBuy281,963$34.86$9,829,230.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Felix BakerDirectorBuy189,611$34.07$6,460,046.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/3/2014Clay SiegallCEOSell5,600$43.34$242,704.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Clay SiegallCEOSell100,000$51.97$5,197,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Eric DobmeierCOOSell56,010$47.92$2,683,999.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2014Jonathan DrachmanCMOSell1,201$45.75$54,945.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2013Felix BakerDirectorBuy407,078$39.66$16,144,713.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013Felix BakerDirectorBuy1,005,901$43.19$43,444,864.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2013Clay B SiegallCEOSell2,000$43.87$87,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2013Eric DobmeierCOOSell42,000$46.40$1,948,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2013Eric DobmeierCOOSell75,000$42.64$3,198,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Clay B SiegallCEOSell102,000$43.90$4,477,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013David W GryskaDirectorSell10,000$42.48$424,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2013Todd SimpsonCFOSell37,763$41.45$1,565,276.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013Clay SiegallCEOSell7,653$40.91$313,084.23View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013Eric DobmeierCOOSell3,328$40.91$136,148.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013Vaughn HimesEVPSell1,736$40.91$71,019.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Clay B SiegallCEOSell2,000$40.03$80,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/12/2013Todd E SimpsonCFOSell92,527$37.45$3,465,136.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Clay B SiegallCEOSell2,000$32.59$65,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2013Srinivas AkkarajuDirectorSell5,000$32.75$163,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2013Vaughn B HimesEVPSell10,000$32.11$321,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Clay B SiegallCEOSell2,000$33.88$67,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Srinivas AkkarajuDirectorSell17,500$37.17$650,475.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2013Eric DobmeierCOOSell100,000$29.68$2,968,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2013David W GryskaDirectorSell10,000$27.17$271,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2013Clay B SiegallCEOSell2,000$29.61$59,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2013Thomas C ReynoldsInsiderSell125,079$28.00$3,502,212.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2012Clay B SiegallCEOSell8,250$25.51$210,457.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2012Clay B SiegallCEOSell8,250$26.54$218,955.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Seattle Genetics (NASDAQ:SGEN)
DateHeadline
07/27/16 06:46 PMCantor Fitzgerald Cuts Rating On Seattle Genetics, Inc. (SGEN) - Finance Daily
07/27/16 08:06 AMSeattle Genetics' (SGEN) Loss Narrower than Expected in Q2 -
07/27/16 06:27 AMSeattle Genetics downgraded by Cantor Fitzgerald -
07/27/16 12:37 AMEdited Transcript of SGEN earnings conference call or presentation 26-Jul-16 8:30pm GMT -
07/26/16 06:46 PMEARNINGS SUMMARY: Details of Seattle Genetics Inc. Q2 Earnings Report
07/26/16 06:46 PMSeattle Genetics revenue rises on drug sales, licensing agreements
07/26/16 06:46 PMSeattle Genetics Reports Second Quarter 2016 Financial Results
07/26/16 03:53 PMSeattle Genetics reports 2Q loss -
07/26/16 09:47 AMSeattle Genetics Inc Earnings Call (Q2 2016)
07/26/16 06:07 AMQ2 2016 Seattle Genetics Inc Earnings Release - After Market Close -
07/20/16 07:17 PMShares of Seattle Genetics (SGEN) Rally 3.64% - Trade Calls
07/20/16 07:17 PMEquity Roundup: Stock Performance Focus on Seattle Genetics, Inc. (NASDAQ:SGEN) - Press Telegraph
07/20/16 07:17 PMHow Many Seattle Genetics, Inc. (NASDAQ:SGEN)'s Analysts Are Bullish? - Consumer Eagle
07/20/16 07:17 PMShares Positive Over the Past Month: Seattle Genetics, Inc. (NASDAQ:SGEN) - TGP
07/19/16 06:30 PMSeattle Genetics and Takeda Announce Publication of Final …
07/19/16 06:30 PMSeattle Genetics treatment results in complete remission for group of lymphoma patients
07/19/16 06:30 PMSeattle Genetics (SGEN), Takeda Announces Publication of Final ADCETRIS Phase 2 Data in r/r Hodgkin Lymphoma
07/19/16 07:30 AMSeattle Genetics (SGEN), Takeda Announces Publication of Final ADCETRIS Phase 2 Data in r/r Hodgkin Lymphoma - StreetInsider.com
07/18/16 09:03 AM10:03 am Seattle Genetics & Takeda Pharma (TKPYY) announce final data of the Adcetris monotherapy pivotal Phase 2 clinical trial in relapsed or refractory classical Hodgkin lymphoma were published in t -
07/18/16 09:00 AMSeattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood - [Business Wire] - BOTHELL, Wash., CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESSWIRE)-- Seattle Genetics, Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced the final data of the ADCETRIS ...
07/16/16 05:46 PMRedmile Group LLC Decreased Stake in Seattle Genetics INC (NASDAQ:SGEN) by $14.08 Million as Shares Declined - Consumer Eagle
07/16/16 05:46 PMShare Performance Summary for: Seattle Genetics, Inc. (NASDAQ:SGEN) - Press Telegraph
07/16/16 10:41 AM3 Primary Ways Researchers Are Combatting Cancer -
07/16/16 09:36 AMStock in Positive Territory for the Quarter: Seattle Genetics, Inc. (NASDAQ:SGEN) - Engelwood Daily
07/16/16 09:36 AMStrong Sell Calls For Seattle Genetics, Inc. (NASDAQ:SGEN) At 0 - Investor Newswire
07/15/16 05:21 PMSEATTLE GENETICS INC /WA : Change in Directors or Principal Officers (form 8-K)
07/15/16 03:41 PMSEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers -
07/15/16 11:37 AMSeattle Genetics, Inc. (NASDAQ:SGEN) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/15/16 11:37 AMSeattle Genetics Inc Realized Volatility Hits Elevated Level - CML News
07/15/16 11:37 AMBroker Outlook For Seattle Genetics, Inc. (NASDAQ:SGEN) - Fiscal Standard
07/13/16 07:00 AMSeattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2016 Financial Results on July 26, 2016 - [Business Wire] - Seattle Genetics, Inc. announced today that it will report its second quarter 2016 financial results on Tuesday, July 26 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
07/12/16 10:43 AMSeattle Genetics, Inc. (NASDAQ:SGEN) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/12/16 10:43 AMShares Moving Up Over the Past Quarter: Seattle Genetics, Inc. (NASDAQ:SGEN) - Engelwood Daily
07/12/16 10:43 AMOption Market: Seattle Genetics Inc Risk Hits An Inflection Point - CML News
07/12/16 10:43 AMAnalyst's Notable Buzzers: Edwards Lifesciences Corporation (NYSE:EW) , Seattle Genetics, Inc. (NASDAQ:SGEN) - Street Updates
07/10/16 05:37 PMNext Weeks Broker Price Targets For Seattle Genetics, Inc. (NASDAQ:SGEN) - Fiscal Standard
07/10/16 10:20 AMEventide Asset Management LLC Increased Seattle Genetics INC (NASDAQ:SGEN) by $10.16 Million as Shares ... - Engelwood Daily
07/10/16 10:20 AMStock Performance Rundown on: Seattle Genetics, Inc. (NASDAQ:SGEN) - Press Telegraph
07/08/16 09:14 AMForm 4 SEATTLE GENETICS INC For: Jul 06 Filed by: SIEGALL CLAY B
07/07/16 06:26 PMCompany Stock Focus for Seattle Genetics, Inc. (NASDAQ:SGEN): Which Way Will Shares Head? - Press Telegraph
07/07/16 06:26 PMCan Seattle Genetics, Inc. (NASDAQ:SGEN) Improve on the Earnings Front? - Engelwood Daily
07/07/16 06:26 PMSeattle Genetics Incorporated (NASDAQ:SGEN) Shorted Shares Increased 0.08% After Market Selling - Engelwood Daily
07/07/16 06:26 PMSeattle Genetics (SGEN) : Analyst Rating Update - Trade Calls
07/07/16 05:21 PMSeattle Genetics/Takeda Adectris' Label Expanded in the EU -
07/06/16 06:46 PMShares of Seattle Genetics (SGEN) Sees Large Inflow of Net Money Flow - Trade Calls
07/06/16 06:46 PMInsiders Increasing Positions in: Seattle Genetics, Inc. (NASDAQ:SGEN) - Press Telegraph
07/06/16 09:20 AMSeattle Genetics drug gets OK for additional cancer therapies in Europe -
07/04/16 10:55 AMShare Performance Recap for: Seattle Genetics, Inc. (NASDAQ:SGEN) - Press Telegraph
07/04/16 10:55 AMWill Seattle Genetics, Inc. (NASDAQ:SGEN) Surprise This Quarter? - Investor Newswire
07/02/16 09:01 AMSeattle Genetics, Inc. (NASDAQ:SGEN) Expected to Reach Highs Of $65 - Investor Newswire

Social

About Seattle Genetics

Seattle Genetics logoSeattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company's product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company's pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: SGEN
  • CUSIP: 81257810
Key Metrics:
  • Previous Close: $47.98
  • 50 Day Moving Average: $40.85
  • 200 Day Moving Average: $36.52
  • P/E Ratio: N/A
  • P/E Growth: -2.31
  • Market Cap: $6.73B
  • Beta: 1.76
  • Current Year EPS Consensus Estimate: $-1.09 EPS
  • Next Year EPS Consensus Estimate: $-0.88 EPS
Additional Links:
Seattle Genetics (NASDAQ:SGEN) Chart for Wednesday, July, 27, 2016